Statens Serum Institut
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- -
- Established
- 1902-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://www.ssi.dk/
A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis(TB) Subunit Vaccine
Phase 1
Completed
- Conditions
- Tuberculosis
- Interventions
- Biological: 50 microgram antigen (Ag85B + ESAT-6) + 500 nmol KLK + 20 nmol ODN1aBiological: 50 microgram antigen (Ag85B + ESAT-6)Biological: 50 microgram antigen (Ag85B + ESAT-6) + 100 nmol KLK + 4 nmol ODN1a
- First Posted Date
- 2009-10-28
- Last Posted Date
- 2013-01-21
- Lead Sponsor
- Statens Serum Institut
- Target Recruit Count
- 36
- Registration Number
- NCT01003093
- Locations
- 🇳🇱
Leiden University Medical Centre, Leiden, RC Leiden, Netherlands
A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis (TB) Subunit Vaccine in Purified Protein Derivative (PPD) Positive Volunteers
Phase 1
Completed
- Conditions
- Tuberculosis
- Interventions
- Biological: 50 microg. antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)
- First Posted Date
- 2009-06-29
- Last Posted Date
- 2013-01-21
- Lead Sponsor
- Statens Serum Institut
- Target Recruit Count
- 20
- Registration Number
- NCT00929396
- Locations
- 🇳🇱
Leiden University Medical Centre, Leiden, RC Leiden, Netherlands
Trial on the Safety of a New Liposomal Adjuvant System, CAF01, When Given With the Tuberculosis Subunit Vaccine Ag85B-ESAT-6 as Two Injections With Two Months Interval to Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Tuberculosis
- Interventions
- Biological: 50 µg Ag85B-ESAT-6 aloneBiological: 50 µg Ag85B-ESAT-6 + 125/25 µg CAF01Biological: 50 µg Ag85B-ESAT-6 + 313/63 µg CAF01Biological: 50 µg Ag85B-ESAT-6 + 625/125 µg CAF01
- First Posted Date
- 2009-06-17
- Last Posted Date
- 2013-01-21
- Lead Sponsor
- Statens Serum Institut
- Target Recruit Count
- 38
- Registration Number
- NCT00922363
- Locations
- 🇳🇱
Department of infectious diseases, C5-P, LUMC, Leiden, Netherlands
Vaccination With Autologous Dendritic Cells Pulsed With HIV-Antigens for Treatment of Patients With Chronic HIV-Infection
Phase 1
Completed
- Conditions
- HIV Infections
- First Posted Date
- 2009-03-05
- Last Posted Date
- 2009-04-08
- Lead Sponsor
- Statens Serum Institut
- Target Recruit Count
- 12
- Registration Number
- NCT00856154
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, Denmark
Safety and Risk of Sensitisation of the rdESAT-6 + rCFP-10 Skin Test Following Repeated Intradermal Administration
Phase 1
Completed
- Conditions
- Tuberculosis
- Interventions
- Biological: rdESAT-6 + rCFP-10
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2013-01-21
- Lead Sponsor
- Statens Serum Institut
- Target Recruit Count
- 42
- Registration Number
- NCT00793702
- Locations
- 🇩🇰
Rigshospitalet, Epidemiklinikken, Copenhagen, Denmark
Infectious Causes of Uveitis
Completed
- Conditions
- Uveitis
- First Posted Date
- 2008-05-13
- Last Posted Date
- 2014-05-15
- Lead Sponsor
- Statens Serum Institut
- Target Recruit Count
- 100
- Registration Number
- NCT00676624
- Locations
- 🇩🇰
Glostrup Hospital, Glostrup, Denmark
Safety and Immunogenicity of a New Serum-free DTaP-IPVvero Combination Vaccine
Phase 3
Completed
- Conditions
- Active Immunization
- Interventions
- Biological: DTaP-IPV vero vaccineBiological: DTaP-IPV mkc vaccine
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2013-01-21
- Lead Sponsor
- Statens Serum Institut
- Target Recruit Count
- 817
- Registration Number
- NCT00655148
- Locations
- 🇵🇱
Centre Bydgoszcz, Bydgoszcz, Poland
🇵🇱Centre Krakow, Krakow, Poland
🇵🇱Centre Lodz, Lodz, Poland
Rickettsial Genesis to Sarcoidosis in Denmark
Completed
- Conditions
- SarcoidosisRickettsia Infections
- First Posted Date
- 2006-05-17
- Last Posted Date
- 2009-03-09
- Lead Sponsor
- Statens Serum Institut
- Target Recruit Count
- 36
- Registration Number
- NCT00326534
- Locations
- 🇩🇰
Denmark, Copenhagen S, Denmark
© Copyright 2025. All Rights Reserved by MedPath